These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 18380812

  • 21. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
    Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ.
    Am J Epidemiol; 2004 Dec 01; 160(11):1059-69. PubMed ID: 15561985
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Prostate cancer: update on screening].
    Grosclaude P.
    Bull Acad Natl Med; 2008 May 01; 192(5):1013-8; discussion 1019. PubMed ID: 19238790
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates.
    Di Matteo L, Di Matteo R.
    Eur J Health Econ; 2005 Dec 01; 6(4):298-308. PubMed ID: 16180027
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan.
    Ito K, Kakehi Y, Naito S, Okuyama A, Japanese Urological Association.
    Int J Urol; 2008 Sep 01; 15(9):763-8. PubMed ID: 18786203
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
    Colli JL, Amling CL.
    Prostate Cancer Prostatic Dis; 2008 Sep 01; 11(3):247-51. PubMed ID: 18268527
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prostate specific antigen best practice statement: 2009 update.
    Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P.
    J Urol; 2009 Nov 01; 182(5):2232-41. PubMed ID: 19781717
    [Abstract] [Full Text] [Related]

  • 38. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R, Gulati R, Falcon S, Penson DF.
    Med Decis Making; 2008 Nov 01; 28(3):323-31. PubMed ID: 18319508
    [Abstract] [Full Text] [Related]

  • 39. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.
    Collette L, Burzykowski T, Schröder FH.
    Eur J Cancer; 2006 Jul 01; 42(10):1344-50. PubMed ID: 16730974
    [Abstract] [Full Text] [Related]

  • 40. [Evaluation of mass screening for prostatic cancer].
    Nakagawa S.
    Nihon Rinsho; 2002 Dec 01; 60 Suppl 11():289-93. PubMed ID: 12599587
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.